##  [Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs](/us-en/news/media-releases/novartis-data-finds-relapsing-ms-patients-gilenya-had-greater-treatment-retention-and-satisfaction-rates-vs-injectable-dmts-0 "Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs") 

  Sep 16, 2016